Economic Observation Network RuiZhi Pharmaceutical (300149) disclosed relevant operating data for the first half of the year, with a significant year-on-year decline in gross profit margin and a significant increase in accounts receivable.

Performance and business situation:
The gross profit margin for the first half of the year was 23.66%, a year-on-year decrease of 18.46 percentage points Income is increasing, but the ability to make money is rapidly deteriorating, indicating pressure on order quality or price. Accounts receivable increased by 36.09% year-on-year, with a high accounts receivable/profit ratio of 1875% While increasing income, the collection of funds has slowed down, and the quality of cash flow is questionable - although the operating cash flow is still 39.97 million, it has also decreased by 38.8% year-on-year 。

The above content is based on publicly available information and does not constitute investment advice.